Yearly zoledronic acid in postmenopausal osteoporosis [5]

New England Journal of Medicine

Volumn 357, Issue 7, 2007, Pages 713-714

  Chang, Jennie T ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CREATININE; PLACEBO; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE;

CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG LABELING; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEART ATRIUM FIBRILLATION; HUMAN; KIDNEY FAILURE; LETTER; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; SIDE EFFECT; DRUG ADMINISTRATION; FEMALE; FRACTURE; METHODOLOGY; NOTE; CHEMICALLY INDUCED DISORDER;

BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; FEMALE; FRACTURES, BONE; HUMANS; IMIDAZOLES; OSTEOPOROSIS, POSTMENOPAUSAL; PLACEBOS; RESEARCH DESIGN; KIDNEY FAILURE;

EID: 34547941220     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: None     Document Type: Letter

References (4)

1. Compston J. Treatments for osteoporosis - looking beyond the HORIZON. N Engl J Med 2007;356:1878-80.
2. Chang JT, Green L, Beitz J. Renal failure with the use of zoledronic acid. N Engl J Med 2003;349:1676-8.
3. Markowitz GS, Fine PL, Stack JI, et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 2003;64:281-9.
4. Zometa product label. East Hanover, NJ: Novartis Pharmaceuticals, 2002. (Accessed July 26, 2007, at http://www.us.zometa.com/info/about/index.jsp.)